Trastuzumab
Her2 (Human Epidermal Growth Factor Receptor 2) Inhibitors
Sold as Tuznue · Zercepac · Dazublys · Herwenda · Hervelous
- Drug class
- Her2 (Human Epidermal Growth Factor Receptor 2) Inhibitors
- Availability
- See label
- Routes
- Intravenous, Subcutaneous
- Markets covered
- 3
- Products on record
- 59
Overview
Trastuzumab is an active pharmaceutical ingredient in the Her2 (Human Epidermal Growth Factor Receptor 2) Inhibitors group (L01FD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 33 | May 29, 2026 |
| CA Canada | Health Canada | 16 | April 13, 2026 |
| EU European Union | EMA | 10 | May 18, 2026 |
GBUnited Kingdom· MHRA
33 products
Uses
Breast cancer Metastatic breast cancer Trazimera is indicated for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease.
Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
- in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
- in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. 1). - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
CACanada· Health Canada
16 products
Uses
Indications have been granted on the basis of similarity between OGIVRI and the reference biologic drug HERCEPTIN.
OGIVRI (trastuzumab) is indicated for:
Early Breast Cancer (EBC) OGIVRI (trastuzumab) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, • following surgery and after chemotherapy • following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel • in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
4 Clinical Trials – Reference Biologic Drug section. Based on the analysis of the HERA trial, the benefit of the adjuvant treatment with trastuzumab for low risk patients not given adjuvant chemotherapy are unknown. e. concurrent versus sequential, anthracycline containing versus non-anthracycline containing) was not studied.
EUEuropean Union· EMA
10 products
Uses
Breast cancer Metastatic breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease.
Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
- in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
- in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. Early breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).
Drug interactions
Known interactions involving Trastuzumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000571679 · revised January 30, 2026
- [2]Health Canada (DPD) · 02474425 · revised July 31, 2025
- [3]European Medicines Agency · EMEA/H/C/005209 · revised May 18, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.